NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01524978 2017-11-20A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive CancersHoffmann-La RochePhase 2 Completed208 enrolled 26 charts
NCT02115035 2014-08-27A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered VemurafenibUniversity of ArkansasPhase 1/2 Withdrawn